Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered with Routine Pediatric Vaccines: A European Randomized Controlled Trial.

ABSTRACT:

Introduction

The immunogenicity and safety of MenACYW-TT (MenQuadfi^®) were compared to another quadrivalent meningococcal conjugate vaccine, MCV4-TT (Nimenrix^®), when administered in infants alongside routine childhood vaccines in Europe.

Methods

One set of healthy infants was randomized 1:1 to receive MenACYW-TT (group 1; n = 714) or MCV4-TT (group 2; n = 726) at age 2, 4, and 12-18 months (2 + 1 regimen) concomitantly with routine vaccines (including 10-valent pneumococcal conjugate vaccine). Another set was randomized 1:1 to receive MenACYW-TT in a 2 + 1 regimen (group 3; n = 112) or a 3 + 1 regimen at age 2, 4, 6, and 12-18 months (group 4; n = 108) concomitantly with routine vaccines (including 13-valent pneumococcal conjugate vaccine). Immune resp

SUBMITTER: Martinon-Torres F 

PROVIDER: S-EPMC12339823 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature